White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia

被引:0
|
作者
Fang, Jacob [1 ]
Bosma, Grace [2 ]
Aisner, Dara [3 ]
McMahon, Christine [2 ]
Amaya, Maria [2 ]
Schwartz, Marc [2 ]
Kaiser, Jeff [2 ]
Abbott, Diana [2 ]
Pan, Zenggang [3 ]
Schowinsky, Jeffrey [3 ]
Pang, Changlee [3 ]
Gutman, Jonathan A. [2 ]
Pollyea, Daniel A. [2 ]
机构
[1] Univ Colorado, Sch Med, Aurora, CO 80045 USA
[2] Univ Colorado, Div Med Hematol, Aurora, CO USA
[3] Univ Colorado, Div Pathol, Aurora, CO USA
关键词
Acute myeloid leukemia; predictive factors; WBC nadir; induction chemotherapy; stem cell transplant; overall survival; progression free survival; INDUCTION; ADULTS;
D O I
10.1080/10428194.2024.2323677
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Predictors for response to intensive therapy in AML have focused on baseline factors: percent leukemic blasts in marrow, cytogenetic/molecular genetic abnormalities, and presence of secondary AML. Non-baseline dynamic factors, occurring after induction but before response, may be useful for decisions related to salvage chemotherapy. We hypothesized white blood cell (WBC) count nadir after induction may be a real time indicator of treatment efficacy. We also examined whether time to stem cell transplant (SCT) or baseline molecular genetic abnormalities are associated with a low nadir. Data showed WBC nadir = 0 was a negative predictor for response to intensive induction and was correlated with reduced overall survival and progression free survival. Patients with WBC nadir = 0 did not have a significantly longer time to SCT, and none of the mutations increased the likelihood of reaching WBC nadir = 0. WBC nadir may be a useful real-time monitor in AML patients receiving intensive induction chemotherapy.
引用
收藏
页码:800 / 807
页数:8
相关论文
共 50 条
  • [31] Platelet to white blood cell ratio was an independent prognostic predictor in acute myeloid leukemia
    Zhao, Shuqi
    Pan, Hanzhang
    Guo, Qi
    Xie, Wanzhuo
    Wang, Jinghan
    HEMATOLOGY, 2022, 27 (01) : 426 - 430
  • [32] Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
    Yamamoto, Kazuhito
    Shinagawa, Atsushi
    DiNardo, Courtney D.
    Pratz, Keith W.
    Ishizawa, Kenichi
    Miyamoto, Toshihiro
    Komatsu, Norio
    Nakashima, Yasuhiro
    Yoshida, Chikashi
    Fukuhara, Noriko
    Usuki, Kensuke
    Yamauchi, Takahiro
    Asada, Noboru
    Asou, Norio
    Choi, Ilseung
    Miyazaki, Yasushi
    Honda, Hideyuki
    Okubo, Sumiko
    Kurokawa, Misaki
    Zhou, Ying
    Zha, Jiuhong
    Potluri, Jalaja
    Matsumura, Itaru
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (01) : 29 - 38
  • [33] Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy
    Leroy, Harmony
    Gadaud, Noemie
    Berard, Emilie
    Klein, Emilie
    Luquet, Isabelle
    Vial, Jean-Philippe
    Rieu, Jean-Baptiste
    Lechevalier, Nicolas
    Tavitian, Suzanne
    Leguay, Thibaut
    Largeaud, Laetitia
    Bidet, Audrey
    Delabesse, Eric
    Sarry, Audrey
    de Grande, Anne-Charlotte
    Recher, Christian
    Pigneux, Arnaud
    Bertoli, Sarah
    Dumas, Pierre-Yves
    CANCER MEDICINE, 2024, 13 (03):
  • [34] Intracranial hemorrhage in newly diagnosed non-promyelocytic acute myeloid leukemia patients admitted for intensive induction chemotherapy
    Koschade, Sebastian E.
    Stratmann, Jan A.
    Miesbach, Wolfgang
    Steffen, Bjoern
    Serve, Hubert
    Finkelmeier, Fabian
    Brandts, Christian H.
    Ballo, Olivier
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 108 (02) : 125 - 132
  • [35] Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy
    El-Jawahri, Areej
    Abel, Gregory A.
    Traeger, Lara
    Waldman, Lauren
    Markovitz, Netana
    VanDusen, Harry
    Fathi, Amir
    Steensma, David P.
    LeBlanc, Thomas W.
    Horick, Nora K.
    DeAngelo, Daniel J.
    Wadleigh, Martha
    Hobbs, Gabriela
    Foster, Julia
    Brunner, Andrew M.
    Amrein, Philip
    Stone, Richard M.
    Temel, Jennifer S.
    Greer, Joseph A.
    LEUKEMIA, 2019, 33 (10) : 2393 - 2402
  • [36] Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFβ/MYH11 rearrangement
    Martín, G
    Barragán, E
    Bolufer, P
    Chillón, C
    García-Sanz, R
    Gómez, T
    Brunet, S
    González, M
    Sanz, MA
    HAEMATOLOGICA, 2000, 85 (07) : 699 - 703
  • [37] Outcomes Following Hematopoietic Stem Cell Transplantation in Patients Treated With Chemotherapy With or Without Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
    Lambert, J.
    Raffoux, E.
    Chantepie, S.
    Gastaud, L.
    Legrand, O.
    Marolleau, J. -P.
    Pautas, C.
    de Latour, R. Peffault
    Thomas, X.
    Turlure, P.
    Benner, R. J.
    Vandendries, E.
    Gogat, K.
    Dombret, H.
    Castaigne, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 36 - 37
  • [38] Predictive Factors of Response and Survival following Chemotherapy Treatment in Acute Myeloid Leukemia Progression from Myelodysplastic Syndrome
    Kobayashi, Hiroyuki
    Matsuyama, Tomohiro
    Ueda, Masuzu
    Suzuki, Takahiro
    Ozaki, Katsutoshi
    Mori, Masaki
    Nagai, Tadashi
    Muroi, Kazuo
    Ozawa, Keiya
    INTERNAL MEDICINE, 2009, 48 (18) : 1629 - 1633
  • [39] Comorbidity as a risk factor for overall survival and decision criteria for intensity of chemotherapy in elderly patients with acute myeloid leukemia
    Irena Djunic
    Marijana Virijevic
    Aleksandra Novkovic
    Vladislava Djurasinovic
    Natasa Colovic
    Ana Vidovic
    Nada Suvajdzic-Vukovic
    Dragica Tomin
    Medical Oncology, 2012, 29 : 1077 - 1081
  • [40] Comorbidity as a risk factor for overall survival and decision criteria for intensity of chemotherapy in elderly patients with acute myeloid leukemia
    Djunic, Irena
    Virijevic, Marijana
    Novkovic, Aleksandra
    Djurasinovic, Vladislava
    Colovic, Natasa
    Vidovic, Ana
    Suvajdzic-Vukovic, Nada
    Tomin, Dragica
    MEDICAL ONCOLOGY, 2012, 29 (02) : 1077 - 1081